Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.
The immunobiology of immunotherapy
Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.
EVEN MORE SEMINARS
Professor A. Graham Pockley multimmune GmbH / Nottingham Trent University
A new era of cancer therapeutics?
Mohamed Torky Hospital Germans Trias i pujol. Barcelona. Spain
Role of Radial-EBUS in diagnosis of lung cancer.
Mr Naga Venkatesh Jayanthi MD, FRCS Bupa - Consultant Surgeon
Minimal Invasive Oesophagectomy – where are we going?
Chris Curtis The Swallows Head & Neck Cancer Charity
A patient’s journey ‘Cancer to the palace in 6yrs’
Emlyn Samuel Cancer Research UK
Brexit: getting the best outcome for research and patients